Associations between duration of status epilepticus and clinical outcomes in adults: a systematic review.

J NeurolOct 6, 2026 (epub)
Clinical ResearchNeurologyOpen access

Fabio Iannaccone, Claudia Scarpitta, Elisa De Rossi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the relationship between the duration of status epilepticus (SE) and clinical outcomes in adults, analyzing 43 studies. It found that longer SE duration is more consistently associated with worse functional outcomes than with mortality, suggesting that SE duration should be viewed as a context-dependent prognostic marker.

Key findings

  • Longer SE duration is more consistently linked to worse functional outcomes than mortality.
  • Mortality was assessed in 31 studies, with varied definitions of SE duration.
  • The evidence on refractoriness suggests a connection between prolonged seizures and treatment resistance.
  • Standardized criteria for SE duration could enhance prognostic assessment.

Why it matters

Understanding the implications of SE duration on clinical outcomes is crucial for guiding treatment decisions and improving patient management. Clinicians should consider the context of SE duration when evaluating prognosis.

Source

PubMed · PMID 42836884Free full text on PubMed Central

Published in J Neurol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.